Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]

Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characte...

Full description

Bibliographic Details
Main Author: Jun Yamagami
Format: Article
Language:English
Published: F1000 Research Ltd 2018-08-01
Series:F1000Research
Online Access:https://f1000research.com/articles/7-1360/v1
id doaj-e4631352a72b4ef786c7073915bfaa49
record_format Article
spelling doaj-e4631352a72b4ef786c7073915bfaa492020-11-25T03:51:01ZengF1000 Research LtdF1000Research2046-14022018-08-01710.12688/f1000research.14474.115758Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]Jun Yamagami0Department of Dermatology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, JapanPemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.https://f1000research.com/articles/7-1360/v1
collection DOAJ
language English
format Article
sources DOAJ
author Jun Yamagami
spellingShingle Jun Yamagami
Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
F1000Research
author_facet Jun Yamagami
author_sort Jun Yamagami
title Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
title_short Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
title_full Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
title_fullStr Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
title_full_unstemmed Recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
title_sort recent advances in the understanding and treatment of pemphigus and pemphigoid [version 1; referees: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2018-08-01
description Pemphigus and pemphigoid are characterized as autoimmune blistering diseases in which immunoglobulin G autoantibodies cause blisters and erosions of the skin or mucosa or both. Recently, understanding of the pathophysiology of pemphigus and pemphigoid has been furthered by genetic analyses, characterization of autoantibodies and autoreactive B cells, and elucidation of cell–cell adhesion between keratinocytes. For the management of pemphigus and pemphigoid, the administration of systemic corticosteroids still represents the standard treatment strategy; however, evidence of the efficacy of therapies not involving corticosteroids, such as those employing anti-CD20 antibodies, is increasing. The goal should be to develop antigen-specific immune suppression-based treatments.
url https://f1000research.com/articles/7-1360/v1
work_keys_str_mv AT junyamagami recentadvancesintheunderstandingandtreatmentofpemphigusandpemphigoidversion1referees2approved
_version_ 1724489228050497536